This guideline recommends that iOAT should be considered for individuals with severe, treatment refractory opioid use disorder and ongoing illicit injection opioid use; that both diacetylmorphine and hydromorphone may be appropriate treatment options; and that iOAT should be provided as an open-ended treatment, with decisions to transition to oral OAT made in collaboration with the patient. This clinical guideline was developed to provide three key clinical recommendations as well as clinical guidance on the provision of iOAT. Recommendations and clinical guidance are based on a structured literature review and clinical expertise. Its partner document, National Injectable Opioid Agonist Treatment for Opioid Use Disorder Operational Guidance, provides guidance on the implementation, operation, and evaluation of iOAT programs.
